Skip to main
LUCD
LUCD logo

Lucid Diagnostics (LUCD) Stock Forecast & Price Target

Lucid Diagnostics (LUCD) Analyst Ratings

Based on 5 analyst ratings
Strong Buy
Strong Buy 80%
Buy 20%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Lucid Diagnostics Inc. demonstrates a promising outlook due to its advantageous position in the market for gastroesophageal reflux disease diagnostics, particularly with its leading products, EsoCheck and EsoGuard. The company is making strides with Medicare, indicating that favorable coverage is likely to be announced, which could enhance revenue potential and market penetration. Additionally, Lucid's first mover advantage with EsoGuard and its superior testing capabilities position it as an attractive acquisition target, signifying strong long-term growth prospects.

Bears say

Lucid Diagnostics Inc reported a pro forma net loss of $9.9 million, translating to an earnings per share (EPS) of $(0.10), which was worse than both the company's estimates and market consensus. The company's performance in processing EsoGuard tests significantly declined, with only 2,756 tests conducted in Q2, marking a downward trend from previous quarters and raising concerns about demand and market traction. Additionally, various risks, including liquidity issues, regulatory approvals, and competition, further contribute to the negative outlook for the stock, indicating challenges in achieving sustainable growth and profitability.

Lucid Diagnostics (LUCD) has been analyzed by 5 analysts, with a consensus rating of Strong Buy. 80% of analysts recommend a Strong Buy, 20% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Lucid Diagnostics and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Lucid Diagnostics (LUCD) Forecast

Analysts have given Lucid Diagnostics (LUCD) a Strong Buy based on their latest research and market trends.

According to 5 analysts, Lucid Diagnostics (LUCD) has a Strong Buy consensus rating as of Nov 5, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $3.70, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $3.70, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Lucid Diagnostics (LUCD)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.